Investor Update May 2016
|
|
- Jonah McDaniel
- 5 years ago
- Views:
Transcription
1 Investor Update May 2016 Novo Nordisk poised for growth through helping care for rising global diabetes epidemic On Marsico Capital Management s trip to Australia in March, Portfolio Managers Tom Marsico and Brandon Geisler highlighted how the firm s investment process looks to macro trends which serve as a tailwind to inform its fundamental bottom up work in finding high quality growth companies for Marsico Capital s Global Growth portfolios. One such example revolves around the demographic trends associated with the growing global diabetes epidemic. Rising obesity rates are one of the reasons diabetes rates continue to rise. In the following pages we want to share why we believe this epidemic will continue to worsen and why Denmark-based pharmaceutical company Novo Nordisk is poised for growth. The Opportunity The International Diabetes Federation ( IDF ) estimates that 415 million individuals worldwide currently have diabetes (Exhibit 1). This figure has more than doubled from the year 2000 when 177 million people were estimated to have diabetes. Extrapolating this growth forward, the IDF estimates that 642 million individuals will be living with diabetes by 2040.
2 As Novo Nordisk develops and markets human insulin, insulin analogs, GLP-1 receptor agonists, and other agents for diabetes management, the company should experience long term compounded annual growth that exceeds the overall diabetes market growth rate. Consider that in 2015, Novo Nordisk provided medical treatments to an estimated 26.8 million patients, representing approximately 7% of the global patient population. In addition, when looking at Novo Nordisk s global diabetes market share, the number of patients currently using Novo Nordisk s products would suggest that fewer than 25% of diabetics globally receive diabetes care treatment. The market remains undertreated and the opportunity exists for the number of patients receiving therapy to increase substantially. Given this backdrop, we believe Novo Nordisk is a compelling investment opportunity as its suite of products is specifically indicated for controlling diabetes. Exhibit 1 Source: International Diabetes Federation Globally, China represents the largest demographic group by population, and as it moves from an agrarian economy to a services economy, the country s obesity rates will continue to rise. What is Diabetes? Diabetes is a chronic condition caused by the body s inability to produce or make use of insulin, a hormone made by the pancreas. Insulin acts like a key, unlocking cells so that glucose in the blood can enter and produce energy. Without insulin, blood glucose levels rise and can, over the long term, cause damage to organs and body tissue. 90% of the people with diabetes have type 2 diabetes and up to 70% of type 2 diabetes cases can be prevented or delayed by adopting healthier lifestyles. On the other hand, Type 1 diabetes develops most often in children or young adults, affecting 86,000 children every year 1. There are two primary reasons that diabetes rates are on the rise. First, diabetes rates increase with age. According to the U.S. Centers for Disease Control and Prevention, year olds represent less than 10% of diagnosed diabetes cases. More than 50% of the newly diagnosed individuals are over the age of 55. Much of this is due to the fact that sedentary lifestyle increases with age. Globally, China represents the largest demographic group by population, and as it moves from an agrarian economy to a services economy, the country s obesity rates will continue to rise. Overall, we expect to see an increase in diabetes given the aging of the world s population. Second, diabetes rates rise with obesity rates and while the United States carries the dubious distinction of having the highest proportion of overweight citizens, obesity is a global phenomenon. As emerging 1 International Diabetes Federation, IDF Atlas, 7th edition,
3 market populations earn more discretionary income and move into the middle class, many tend to adopt a Western diet, consuming more calories through meat, fast food and soft drinks, which leads to increased obesity and incidence of diabetes. A Global Epidemic Exhibit 2 We believe the company is the purest way to invest in this theme given 94% of revenues are related to diabetes care and/or insulin used for the treatment of diabetes. Given the aforementioned obesity rates, it would make sense that the portion of the population with diabetes is higher in the United States than in India or China. However, the number of people with the disease in India and China is much greater and is expected to increase significantly (Exhibit 2), reflecting a global epidemic. Around the world, aging demographic trends, obesity rates and the growth of the middle class all contribute to an unfortunate long-term macro tailwind of demand for treatment and a cure for diabetes. Making matters worse, diabetes is a life long illness. Once a person develops the disease, it is with him or her for life. The company that is best positioned, in our view, to meet these ongoing demands is Novo Nordisk. Why Novo Nordisk? Novo Nordisk is by far the dominant player in global diabetes care. While the company focuses on four disease areas (diabetes, obesity, hemophilia and growth disorders), it has a leading 28% market share of global diabetes care (Exhibit 3). We believe the company is the purest way to invest in this theme given 94% of revenues are related to diabetes care and/or insulin used for the treatment of diabetes. In 2015, Novo Nordisk provided medical treatments to an estimated 26.8 million patients. The company s long term target goal is to reach 40 million people with its diabetes care products by Although this would be considered substantial patient growth, it should be achievable given that there are 415 million people living with diabetes today, only half of whom have been diagnosed. As a result of the large unmet medical need and the continued growth in the incidence of diabetes, Novo Nordisk has established long term financial targets of 10% operating income growth over the next three years. As the company continues to innovate with its next generation insulins product portfolio including Tresiba, Ryzodeg, Xultophy and Saxenda, we believe it should be able to achieve these 3
4 long term targets given its established infrastructure. As the market has moved from traditional insulin to more modern (designer) insulins, Novo Nordisk s revenues have more than doubled in this market and operating margins have improved from 31% to 46%. We anticipate the company will continue to innovate with its product portfolio over time and as a result will remain the global leader in the diabetes market. Exhibit 3 Source: Novo Nordisk, February Primary Revenue Drivers Novo Nordisk s major revenue drivers are in three primary areas: basal (long acting) insulin, prandial (meal time) insulin, and GLP-1 receptor agonists. Levemir is Novo Nordisk s current basal insulin product with total global revenues of $2.8 billion and a current 24% market share of the basal insulin market. In the (basal) insulin market, the risk with product use is that blood sugar levels decrease to abnormally low levels (hypoglycemia). Incidence of hypoglycemia can cause a variety of symptoms such as confusion, seizures, and sometimes death. Importantly, Novo Nordisk recently received approval for its next generation basal insulin, Tresiba, which has been shown in studies to lower the incidence of severe hypoglycemia by more than 35% when compared to the market leader in the basal insulin market, Sanofi s Lantus. As Lantus currently has a greater than 65% market share in the basal insulin market, Novo Nordisk is anticipating moving market share away from Sanofi s product to Tresiba due to the recent positive results of the studies. This is one of the near term opportunities for the company and one we believe Wall Street underestimates. After basal insulin, the next opportunity for Novo Nordisk is in the prandial insulin market with its NovoRapid and NovoMix products which account for $4.8 billion in worldwide revenues. As Novo Nordisk s market share has been more dominant in the basal insulin market, these drugs have experienced five year compound annual growth rates ( CAGR ) of 12% and 7%, respectively. As the market has moved from traditional insulin to more modern (designer) insulins, Novo Nordisk s revenues have more than doubled in this market and operating margins have improved from 31% to 46%. Outside of the insulin market, Novo Nordisk has leading market share in the GLP-1 receptor agonist market at 56% with its product Victoza. GLP-1 mechanisms are a differentiated approach to controlling insulin for diabetics and appear to restore glucose 4
5 sensitivity of the pancreas cells that are depleted due to diabetes. Victoza initially received approval in the EU in 2009 and the U.S. in 2010, and achieved $2.7 billion in revenues by the end of Most recently, the company released data that showed that Victoza significantly reduces the risk of major adverse cardiovascular events over five years when added to the standard of care. As this is the first and only trial to show a reduction in cardiovascular events with the GLP-1 mechanism, this data, when approved by the U.S. Federal Drug Administration, should lead to additional Victoza growth which the market is underappreciating. Catalysts and Valuation Given the opportunity for additional sales growth based on the data seen for Tresiba and Victoza in recent research studies, we believe market participants are underestimating Novo Nordisk s future growth. In addition, because diabetes is a largely unmet medical need and given the expected global growth in the incidence of diabetes, Novo Nordisk has established long term financial targets of 10% operating income growth over the next three years. As the company s marketing team is equipped to offer new drugs without the need to expand personnel, Novo Nordisk is expected to increase revenues at a greater rate than operating expenses. We believe this should lead to higher incremental margins, higher earnings, and greater cash flow than the Street is projecting. For example, in 2015, Novo Nordisk reported 8% constant currency growth, grew operating expenses slower than revenues and reported incremental operating margins of 79%. We believe this trend will continue given the overall market growth and Novo Nordisk s continuing market share gains with Tresiba and Victoza. Marsico Capital is currently modeling a revenue CAGR of 11% and operating income CAGR of 13% for Novo Nordisk, which compares to the Streetprojected revenue CAGR of 8% and operating income CAGR of 7% for this same time period. As a result of this growth, we believe Novo Nordisk warrants a premium multiple as it is expected to have greater growth than its peers in the European pharmaceutical industry and can achieve a price target of $72 by the end of This example is intended for hypothetical, illustrative purposes only. Data above is cited in U.S. dollars, unless otherwise noted. Please keep in mind that our views on investments discussed herein are subject to change at any time and the holdings represented here do not represent all of the securities purchased, sold, or recommended by Marsico Capital. References to specific securities mentioned herein are not to be construed as a recommendation to buy or sell those securities, and it should not be assumed that recommendations made in the future will be profitable or will equal the performance of the securities in this list. Each investment thesis stated above is based on information available to Marsico Capital at the time it was prepared, including statements of good faith beliefs and forward-looking projections. This information is subject to uncertainties and future events that could cause actual results to differ from those expected or projected. 5
6 BREAKING NEWS! Marsico Capital Management Wins Award Institutional Investor names Marsico s Global Growth Equity strategy as best in class The Institutional Investor Awards recognise U.S. money managers in 39 asset classes who stood out in the eyes of the investor community for their exceptional performance, risk management and service. The Institutional Investor award selection process starts with a short-list of top performing managers identified by Institutional Investor magazine s editorial and research teams in consultation with evestment s research team. # Investment strategies are analysed based on factors such as one-, three- and 5-year performance, Sharpe ratio, information ratio, standard deviation and upside market capture. Each category is analysed based on the factors used by institutional investors in their own searches on evestment. # More than 1000 leading U.S. pension plans, foundations, endowments and other institutional investors are then asked to vote for up to three of the top performing managers in each strategy in which they invested during the past year. The Marsico team is proud to have been chosen for this coveted and respected award. There is a great deal of rigour behind Institutional Investor s selection criteria, and we appreciate being recognised for the quality of our investment process, people and performance, said Mr Marsico. Our objective is to help investors achieve their long-term goals. A key differentiator is the way we blend top-down macroeconomic analysis and theme development with bottom-up stock selection. This truly sets us apart from other fund managers, and it s an approach that s been tested in a variety of market conditions. We believe the experience of our team and depth of our internal research are contributing factors in how we ve been able to deliver long-term growth of capital for our investors. Marsico s award-winning global growth strategy can be accessed in Australia by institutional, wholesale and platform investors via Channel Capital. # evestment provides the largest, most comprehensive global database of traditional and alternative strategies, delivered through leading-edge technology Global Growth Strategy Performance Please note - the performance returns set out below are for the US$ Marsico Global Growth Strategy (not the CC Marsico Global Fund which has only recently launched) and have been converted to AUD to illustrate the results achieved. Marsico Global Growth Strategy (US$ monthly returns converted to AUD). Performance is as at 31/03/ Year 3 Years p.a. (%) 5 Years p.a. (%) Since Inception p.a. (%) (02/01/2008) Marsico Global Growth (Gross) MSCI ACWI NR # Annualised Excess Return (Gross)
7 Please note the Marsico Global Growth Strategy is domiciled in the U.S. and is not for offer in Australia. The above performance is for illustrative purposes only. The performance returns set out above for the Marsico Global Growth Strategy is a composite of the performance of similar portfolios managed by MCM. The composite performance returns include non-taxable, discretionary, fee-paying global style accounts that have an objective of long-term growth of capital by investing primarily in the common stocks of US and foreign companies of any size that are selected for their long-term growth potential. The gross performance returns stated are for the Marsico Global Growth Strategy in U.S. Dollars (converted to Australian dollars). # The benchmark refers to the MSCI ACWI Net in USD (converted to Australian dollars). Data source: Morningstar Direct and MCM. The performance information presented represents past performance and does not guarantee future results. Returns have not been examined. Returns shown include the reinvestment of dividends and income. The gross-of-fees performance information presented does not reflect the deduction of investment advisory fees or other fees incurred in the management of an account, which will reduce investment returns. About Marsico Capital Management, LLC (MCM) Marsico Capital is a Denver based Global Equity manager, headed by renowned investment manager Tom Marsico. Marsico Capital manages U.S., international and global equities totalling more than US$4.6 billion. For the past 35 years Tom has been involved in financial markets, but it was in the 1990s at Janus Capital that he made a name for himself as a high-profile health and technology investor. Tom launched Marsico Capital Management in 1997 along with an investment team of 20 people. For more information please visit marsico-funds/ Accessing the CC Marsico Global Fund Australian investors can now access Marsico Capital s high quality growth investing approach via a partnership with multi-affiliate financial services group, Channel Capital. The CC Marsico Global Fund ARSN (the Fund) is an Australian domiciled global equities fund managed by Marsico Capital and offered by Channel Investment Management Limited ACN AFSL The Fund is managed in accordance with the Marsico Global Growth Strategy and is available to sophisticated or wholesale investors only. To register your interest in the Fund - please click here. CC Marsico Global Fund ARSN Responsible Entity: Channel Investment Management Limited ACN AFSL (Channel). Investment Manager: Marsico Capital Management, LLC (MCM). This is general information only and is not intended to provide advice to any particular investor, nor take into account an individual s investment objectives, circumstances or needs. The value of an investment can rise and fall and past performance is not indicative of future performance. This information is not financial product advice and has been prepared without taking into account the objectives, financial situation or needs of any particular person. The information is not intended for any general distribution or publication. Please keep in mind that our views on investments discussed herein are subject to change at any time and the holdings represented here do not represent all of the securities purchased, sold, or recommended by MCM. References to specific securities mentioned herein are not to be construed as a recommendation to buy or sell those securities, should not be assumed to be or have been profitable investments, and are not guaranteed to be in portfolios today. 7
Slide 1. International Operations update. Mike Doustdar EVP International Operations. YASMIN FIEDLER, Germany Yasmin has type 1 diabetes
Slide 1 International Operations update Mike Doustdar EVP International Operations YASMIN FIEDLER, Germany Yasmin has type 1 diabetes Slide 2 Forward-looking statements Novo Nordisk s reports filed with
More informationNOVO NORDISK. Analyst: Recommendation: HOLD DATE: Industry: Drug manufacturers
NOVO NORDISK Analyst: Recommendation: HOLD DATE: 11.11.2015 Industry: Drug manufacturers Share price 375,00 DKK Homepage www.novonordisk.com Ticker NVO Number of shares (000) 2.563.800 Target price 406,14
More informationSlide 1. Financial update and closing remarks. Jesper Brandgaard EVP and CFO. RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A
Slide 1 Financial update and closing remarks Jesper Brandgaard EVP and CFO RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A Slide 2 Forward-looking statements Novo Nordisk s reports filed with or
More informationSlide 1. Welcome and introduction. Lars Rebien Sørensen President & CEO
Slide 1 Lars Rebien Sørensen President & CEO Slide 2 Capital Markets Day 2015 Slide 3 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission
More informationSlide 1. Welcome and strategy update. Lars Fruergaard Jørgensen President and CEO
Slide 1 Lars Fruergaard Jørgensen President and CEO Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including the company
More informationInternational Operations overview and strategy. Maziar Mike Doustdar EVP International Operations. Slide 1
Slide 1 International Operations overview and strategy Maziar Mike Doustdar EVP International Operations KUALA LUMPUR Home of International Operations Business Area Southeast Asia Slide 2 Forward-looking
More informationNovo-Nordisk As (NVO-NYSE) Analyst Note
February 03, 2015 Novo-Nordisk As (NVO-NYSE) Analyst Note NEUTRAL Current Recommendation Prior Recommendation Outperform Date of Last Change 02/10/2014 Current Price (02/02/15) $44.73 Target Price $47.00
More informationPatrick J. Sullivan Chief Executive Officer. January 9, 2018 Investor Presentation
Patrick J. Sullivan Chief Executive Officer January 9, 2018 Investor Presentation Forward Looking Statement This presentation may contain forward-looking statements concerning Insulet's expectations, anticipations,
More informationSlide 1. Investor presentation. London 5 February 2019
Slide Investor presentation London 5 February 209 Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this presentation
More informationWalgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs
Walgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs Second quarter sales up 3.1 percent to record $17.0 billion
More informationChronic illness is a growing market for Novo Nordisk
Chronic illness is a growing market for Novo Nordisk Aslam Dalvi - Associate Portfolio Manager Denmark-based global healthcare company Novo Nordisk traces its origins to the first pioneers in insulin production
More informationZacks Small-Cap Research
Zacks Small-Cap Research Sponsored Impartial - Comprehensive August 29, 2018 David Bautz, PhD 312-265-9471 dbautz@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Opiant Pharmaceuticals,
More informationType 1 Diabetes (T1D) Market Share, Size, Analysis, Growth, Trends and Forecasts to 2024 Hexa Research
Type 1 Diabetes (T1D) Market Share, Size, Analysis, Growth, Trends and Forecasts to 2024 Hexa Research "Type 1 diabetes market size was valued at USD 25.52 billion in 2016 and is expected to exhibit rewarding
More informationUniversal Biosensors, Inc.
Universal Biosensors, Inc. ARBN 121 559 993 Buchan Three Tickers Presentation 18 th September 2013 1 Important Disclaimer This presentation is intended to provide a general outline only and is not intended
More informationThis is a licensed product of Ken Research and should not be copied
1 TABLE OF CONTENTS 1. The US Diabetes Care Devices Market Introduction 1.1. What is Diabetes and it s Types? 2. The US Diabetes Care Devices Market Size, 2007-2013 3. The US Diabetes Care Devices Market
More informationFor personal use only
Cochlear Limited Results for the half year ended 31 December 2011 (H1 F12) Chris Roberts, CEO Neville Mitchell, CFO Cochlear Overview Cochlear Limited (ASX:COH): global leader in implantable devices for
More informationVisionary Private Equity Group is Pleased to Announce its Investment in MEDITE Cancer Diagnostics
Dear VPEG Limited Partner, We hope this investor update finds you well. We're pleased to share with you an important update below on the following: Visionary Private Equity Group is Pleased to Announce
More informationSlide 1. Investor presentation. Copenhagen 1 November 2018
Slide 1 Investor presentation Copenhagen 1 November 2018 Manato Shirley Ohara, Adelia Stewart diagnosed has type with 2 diabetes type 1 diabetes Kanagawa, New Orleans, Japan Louisiana, US Slide 2 Highlights
More informationOur future workforce. Flemming Dahl, Senior Vice President and Head of Quality, Novo Nordisk
Our future workforce Flemming Dahl, Senior Vice President and Head of Quality, Novo Nordisk ISPE Nordic 17. Nov. 2016 2 Who am I? Head of Quality in Novo Nordisk 48 years Danish Married 5 Children [7-19]
More informationOral semaglutide and production expansion. Henrik Wulff EVP Product Supply. Peter Kristensen SVP Global Development
YASMIN FIEDLER Germany Yasmin has type 1 diabetes Slide 1 Oral semaglutide and production expansion Henrik Wulff EVP Product Supply Peter Kristensen SVP Global Development Slide 2 Forward-looking statements
More informationPutting ALK on the right growth trajectory
Putting ALK on the right growth trajectory Økonomisk Ugebrevs Kapitalmarkedseftermiddag 15. marts 2018 Per Plotnikof, VP Corporate Communications and IR Marts 2018 Allergy: a global disease with a large
More informationJanuary 30, 2018 Dow Wilson President and Chief Executive Officer
Acquisition of SIRTeX January 30, 2018 Dow Wilson President and Chief Executive Officer This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. Forward-Looking
More informationQ Investor Kit JANUARY-MARCH 2013
Q1 2013 Investor Kit JANUARY-MARCH 2013 1 Swedish Match reporting segments Snus and snuff - Swedish snus (Scandinavia and US) - Moist snuff (US) - SMPM International Other tobacco products - Cigars (US)
More informationDelMar Pharmaceuticals Inc. (OTCQX: DMPI, Target Price: $5.75)
Equity Healthcare / Biotechnology Update (December 3, 2015) DelMar Pharmaceuticals Inc. (OTCQX: DMPI, Target Price: $5.75) DelMar Pharmaceuticals, Inc. ( DelMar, OTCQX: DMPI) is a clinical stage biotechnology
More informationFor personal use only
HY18 Result Presentation 13 February 2018 Dig Howitt Brent Cubis CEO & President CFO HY18 Result highlights Strong momentum across developed markets continues Developed market unit growth up 12% Strengthening
More informationSlide 1. First six months of London 10 August Manato Ohara, diagnosed with type 1 diabetes Kanagawa, Japan
Slide 1 First six months of 2017 London 10 August 2017 Manato Ohara, diagnosed with type 1 diabetes Kanagawa, Japan Slide 2 Agenda Highlights and key events Sales update R&D update Financials and outlook
More informationQ Investor Kit JANUARY-JUNE 2013
Q2 2013 Investor Kit JANUARY-JUNE 2013 1 Swedish Match reporting segments Snus and snuff - Swedish snus (Scandinavia and US) - Moist snuff (US) - SMPM International Other tobacco products - Cigars (US)
More informationQ Investor Kit JANUARY-MARCH 2014
Q1 2014 Investor Kit JANUARY-MARCH 2014 Swedish Match reporting segments Snus and moist snuff Snus (Scandinavia and US) Moist snuff (US) SMPM International Other tobacco products Cigars (US) Chewing tobacco
More informationSlide 1. Investor Presentaton Jefferies Global Healthcare Conference. New York, 7 June Shanghai part of Cities Changing Diabetes
Slide 1 Investor Presentaton Jefferies Global Healthcare Conference New York, 7 June 2016 Shanghai part of Cities Changing Diabetes Slide 2 Forward-looking statements Novo Nordisk s reports filed with
More informationResMed Inc. 36 th Annual J.P. Morgan Healthcare Conference
ResMed Inc. 36 th Annual J.P. Morgan Healthcare Conference Mick Farrell CEO January 8, 2018 Safe Harbor Statement Statements contained in this presentation that are not historical facts are forwardlooking
More informationSmall-Cap Research. Diffusion Pharmaceuticals Inc. (DFFN-NASDAQ) DFFN: FDA Gives Final Guidance for Phase 3 Protocol for TSC in Inoperable GBM OUTLOOK
Small-Cap Research November 16, 2017 David Bautz, PhD 312-265-9471 dbautz@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Diffusion Pharmaceuticals Inc. (DFFN-NASDAQ) DFFN: FDA Gives Final
More informationNovo Nordisk's operating profit decreased by 8% in Danish kroner and increased by 4% in local currencies in the first six months of 2018
report for the period 1 January 2018 to 30 June 2018 8 August 2018 Novo Nordisk's operating profit decreased by 8% in Danish kroner and increased by 4% in local currencies in the first six months of 2018
More informationMDxHealth. Excellent Buy Opportunity. Research Note.
Research Note MDxHealth Excellent Buy Opportunity Chief Research Analyst Marcel Wijma MSc +1 (917) 460 6185 (US) +31 (6) 8489 2954 (NL) m.wijma@leeuwenhoeck.com http://www.leeuwenhoeck.com Date: 29 February
More informationMichael L. Levitz Chief Financial Officer. November 15, 2017 Investor Presentation
Michael L. Levitz Chief Financial Officer November 15, 2017 Investor Presentation Forward Looking Statement This presentation may contain forward-looking statements concerning Insulet's expectations, anticipations,
More informationAltria Group Inc. Ticker: MO
Altria Group Inc. Ticker: MO Business Description Altria Group Inc. through its subsidiaries manufactures and sells cigarettes, other tobacco products, machine-made large cigars and pipe tobacco. It also
More informationQ Investor Kit JANUARY-JUNE 2014
Q2 2014 Investor Kit JANUARY-JUNE 2014 Swedish Match reporting segments Snus and moist snuff Snus (Scandinavia and US) Moist snuff (US) SMPM International Other tobacco products Cigars (US) Chewing tobacco
More informationNEW FRONTIER DATA. ALL RIGHTS RESERVED.
IN PARTNERSHIP WITH NEW FRONTIER DATA. ALL RIGHTS RESERVED. EXECUTIVE SUMMARY The legal cannabis industry is undergoing extraordinary expansion. Following the November 2018 elections, there are now 33
More informationDELICA D:5 ACTIVE GEAR 0
DELICA D:5 ACTIVE GEAR 0 1 1. FY2017 1Q Results 2. FY2017 1Q Results by Region 3. FY2017 Forecast 4. Initiatives for the Future FY2017 1Q Results Summary (vs. FY2016 1Q) (Apr-Jun 2016) (Apr-Jun 2017) (billion
More informationA world leader in allergy immunotherapy
A world leader in allergy immunotherapy Investor Relations presentation June 2017 1 I Investor Relations presentation I June 2017 ALK: Towards redefining treatment of severe allergies The commercial leader
More informationForward-Looking Statements
Investor Presentation May 2012 Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended.
More informationThe Dental Corporation Opportunity
The Dental Corporation Opportunity for Practice Principals. It s the perfect professional collaboration. You focus on dentistry, we look after the paperwork. In recognition of what you, the Practice Principal,
More informationNovo Nordisk increased reported operating profit by 8% in the first six months of 2017 Sales increased by 4% measured in Danish kroner
report for the period 1 January 2017 to 30 June 2017 9 August 2017 Novo Nordisk increased reported operating profit by 8% in the first six months of 2017 Sales increased by 4% measured in Danish kroner
More informationFinancial report for the period 1 January 2017 to 30 September November Novo Nordisk A/S Investor Relations
report for the period 1 January 2017 to 30 September 2017 1 November 2017 Novo Nordisk increased reported operating profit by 5% in the first nine months of 2017 Reported sales increased by 2% to DKK 83.7
More informationSlide 1. Conference call Full year 2018
Slide Conference call Full year 208 Slide 2 Agenda Highlights and key events Sales update R&D update Financials and outlook Slide 3 Forward-looking statements Novo Nordisk s reports filed with or furnished
More informationInvestor Presentation
Investor Presentation February 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities
More informationFRANKFURT SITE TOUR 2017
FRANKFURT SITE TOUR 2017 MEDIA INFORMATION FRANKFURT SITE TOUR 2017 CONTENTS FRANKFURT INSULIN CITY... 4 5 DIABETES BACKGROUNDER... 6 DIABETES STATISTICS... 7 DIABETES MEDICINES... 8 IMAGE BANK... 9 NOTES...
More informationST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015
ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015 1 FORWARD LOOKING STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation
More informationSlide 1. Jefferies 2014 Global Healthcare Conference 5-June Karsten Munk Knudsen CVP of Finance & IT at NNI
Slide 1 Jefferies 2014 Global Healthcare Conference 5-June-2014 Karsten Munk Knudsen CVP of Finance & IT at NNI Slide 2 Agenda Highlights and key events Sales update R&D update Financials and outlook Slide
More informationSlide 1. Investor presentation. Meet the Management London, 9 August 2018
Slide 1 Investor presentation Meet the Management London, 9 August 2018 Manato diagnosed with type 1 diabetes Shirley Ohara, Adelia Stewart has type 2 diabetes Kanagawa, Japan New Orleans, Louisiana, US
More informationShareholder Presentation Annual Meeting 2018
Shareholder Presentation Annual Meeting 2018 FY 18 HIGHLIGHTS Strong sales growth of 2 nd Gen TruScreen to China commenced during 4 th quarter. (50% of the year s sales were generated in the fourth quarter)
More informationHILLENBRAND INDUSTRIES INC
HILLENBRAND INDUSTRIES INC FORM 8-K (Unscheduled Material Events) Filed 2/17/2004 For Period Ending 2/13/2004 Address 700 STATE ROUTE 46 E BATESVILLE, Indiana 47006-8835 Telephone 812-934-7000 CIK 0000047518
More informationQ Investor Kit January December 2014
Q4 2014 Investor Kit January December 2014 Highlights for Q4 Sales up for all product areas and operating profit from product areas up by 8% Scandinavian hoarding for snus prior to tax increase in January
More informationSlide 1. Investor presentation Full year London, 4 February Shanghai part of Cities Changing Diabetes
Slide 1 Investor presentation Full year 2015 London, 4 February 2016 Shanghai part of Cities Changing Diabetes Slide 2 Agenda Highlights and key events Sales update R&D update Financials and outlook Slide
More informationAstraZeneca to Acquire Bristol- Myers Squibb Share of Global Diabetes Alliance. Becoming Global Leaders In Diabetes
AstraZeneca to Acquire Bristol- Myers Squibb Share of Global Diabetes Alliance Becoming Global Leaders In Diabetes 19th December 2013 Cautionary Statement Regarding Forward-Looking Statements In order,
More informationFor personal use only
Australian Securities Exchange Limited Companies Announcements Office SYDNEY 4 April, 2012 New Australian Drug Developer Lists on ASX Key points Growth-focused Australian drug and therapeutic development
More informationInvestor Presentation June 2012 NASDAQ: CEMI
Investor Presentation June 2012 NASDAQ: CEMI Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act
More informationAfter simple testing that only takes minutes people with elevated test results are then recommended to see their physicians for follow-up.
New Medical Device Company Addresses Two Very High Demand Markets with its Proprietary Products. Trader Tracks likes this company as they provide reasonably priced equipment and testing while medical costs
More informationAcquisition of Novartis Influenza Vaccines Business. 27 th October 2014
1 Acquisition of Novartis Influenza Vaccines Business 27 th October 2014 2 Legal Notice Forward looking statements The materials in this presentation speak only as of the date of these materials, and include
More informationBusiness update InvestorDagen
Slide 1 Business update 28 November 2017 Manato Ohara, diagnosed with type 1 diabetes Kanagawa, Japan Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities
More informationSirtex Medical Ltd Buy
Research Sirtex Medical Ltd Buy Price: A$16.32 Price Target: A$20.50 ASX: SRX 21 April 2017 Sirtex Medical (SRX) is a global medical device company which targets cancer therapies, with its lead product
More informationNet profit increased by 1% to DKK 38.6 billion and diluted earnings per share increased by 4% to DKK
report for the period 1 January 2018 to 31 December 2018 1 February 2019 Novo Nordisk's operating profit decreased by 4% in Danish kroner and increased by 3% in local currencies in 2018 Operating profit
More informationSingapore Exchange Limited 1Q FY2009 Financial Results
Singapore Exchange Limited 1Q FY2009 Financial Results 15 October 2008 Singapore Exchange 1 1Q FY2009 Financial Performance NPAT fell 35% from record 1Q FY2008 Operating profit flat compared to 4Q FY2008
More informationPhotocure ASA Executing the Strategy
Photocure ASA Executing the Strategy NOVEMBER 2012 ERIK DAHL, CFO KATHLEEN DEARDORFF, COO Disclaimer The information included in this Presentation contains certain forward-looking statements that address
More informationChina Insulin Industry Report, Jan. 2011
China Insulin Industry Report, 2010 Jan. 2011 This report analyzes the status, competition pattern and development direction of the insulin industry Focuses on the operation and development prospect of
More informationSmall-Cap Research. VolitionRx Ltd (VNRX-NYSE) VNRX: More Positive Data in Colon/Lung Cancers. Anticipating Initial Launch This Year OUTLOOK
Small-Cap Research February 2, 2016 Brian Marckx, CFA bmarckx@zacks.com Ph (312) 265-9474 scr.zacks.com 10 S. Riverside Plaza, Ste 1600, Chicago, IL 60606 VolitionRx Ltd (VNRX-NYSE) VNRX: More Positive
More informationSumitomo Pharmaceuticals reaches a basic agreement to merge with Dainippon Pharmaceutical
For immediate release November 25, 2004 Sumitomo Pharmaceuticals reaches a basic agreement to merge with Dainippon Pharmaceutical Sumitomo Chemical Co., Ltd. announced today that its subsidiary, Sumitomo
More informationLEERINK GLOBAL HEALTHCARE CONFERENCE. Marino Garcia EVP, Chief Strategy Officer February 15, 2017
LEERINK GLOBAL HEALTHCARE CONFERENCE Marino Garcia EVP, Chief Strategy Officer February 15, 2017 SAFE HARBOR STATEMENT This presentation and any statements made for and during any presentation or meeting
More informationFinancial Presentation
Financial Presentation Certain of the statements that will be made during this meeting, as well as statements contained in our 2006 Annual Report to Shareholders and Annual Report on Form 10-K filed with
More informationResults Briefing Junichi Yoshii President & Representative Director
Fiscal Year Ending March 2010 Results Briefing Junichi Yoshii President & Representative Director May 14, 2010 1 Overview of Results (Consolidated) (Million yen) Net sales Operating profit Recurring income
More informationMAGAZINE CAMILLA SYLVEST JOINS EXECUTIVE MANAGEMENT NEW INTERESTING RESULTS WITH SEMAGLUTIDE
MAGAZINE NO 3 217 QUARTERLY INVESTOR UPDATE CAMILLA SYLVEST JOINS EXECUTIVE MANAGEMENT NEW INTERESTING RESULTS WITH SEMAGLUTIDE VICTOZA APPROVED IN THE US AND THE EU AS THE ONLY GLP-1 PRODUCT TO PREVENT
More informationSumitomo Dainippon Pharma to Acquire Tolero Pharmaceuticals, Inc. (US Biotechnology Company)
December 21, 2016 Sumitomo Dainippon Pharma Co., Ltd. Sumitomo Dainippon Pharma to Acquire Tolero Pharmaceuticals, Inc. (US Biotechnology Company) Sumitomo Dainippon Pharma Co., Ltd. (Head office: Osaka,
More informationWorldwide Nanotechnology Dental Implants-- Markets Reach $8.1 By 2015
Worldwide Nanotechnology Dental Implants-- Markets Reach $8.1 By 2015 LEXINGTON, Massachusetts (March 14, 2009) WinterGreen Research announces that it has a new study on Worldwide nanotechnology dental
More informationConsumer Wellness in India Growth Ahead
1 Consumer Wellness in India Growth Ahead Indian Health & Wellness industry Valued at over INR 590 bn, growing at CAGR of 18% - 20% p.a. Growth expected to continue. Industry growth being driven by: Increasing
More informationType 1 Diabetes Australian Research Impact Analysis
Type 1 Diabetes Australian Research Impact Analysis Executive Overview Summary Type 1 diabetes research in Australia Australia is making a significant contribution to the quantity and quality of the global
More informationMDxHealth. Strong outlook for Research Note.
Research Note MDxHealth Strong outlook for 2017 Chief Research Analyst Marcel Wijma MSc +1 (917) 460 6185 (US) +31 (6) 8489 2954 (NL) m.wijma@leeuwenhoeck.com http://www.leeuwenhoeck.com Date: 23 February
More informationHyundai Motor Company 1 st Quarter 2011 Business Results. April 28, 2011
Hyundai Motor Company 1 st Quarter 2011 Business Results April 28, 2011 Cautionary Statement with Respect to Forward-Looking Statements In the presentation that follows and in related comments by Hyundai
More informationSlide 1. Winning with GLP-1. Lars Fruergaard Jørgensen President and CEO. ALEXANDRE DE GREGORIO, Brazil Alexandre has type 2 diabetes
Slide 1 Lars Fruergaard Jørgensen President and CEO ALEXANDRE DE GREGORIO, Brazil Alexandre has type 2 diabetes Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the
More informationCrisis Investing: Profits From a Diabetes Drug About to Get Approved Crisis Investing: Profits From a Diabetes Drug About to Get Approved
Crisis Investing: Profits From a Diabetes Drug About to Get Approved A Special Research Report from Bret Jensen's Biotech Gems Lexicon Pharmaceuticals (Nasdaq: LXRX): tackling one of America s biggest
More informationWntResearch. 100% one-week return? 16 October 2017 PRICE EXPECTATIONS INVESTMENT CASE PRICE TRIGGERS PRICE 12 MONTHS COMPANY PROFILE
Occasion: Initial coverage +37% +71% 100% one-week return? s share price has dropped by more than 50% since the announcement of the current and ongoing public offering. In theory the share price should
More informationPatrick J. Sullivan, President & CEO March 7, 2016 Raymond James 37 th Annual Institutional Conference
Patrick J. Sullivan, President & CEO March 7, 2016 Raymond James 37 th Annual Institutional Conference Forward Looking Statement This presentation may contain forward-looking statements concerning Insulet's
More informationBALCHEM CORPORATION. Q Investor Relations Presentation
BALCHEM CORPORATION Q4 2017 Investor Relations Presentation Balchem Corporation Balchem develops, manufactures, and markets specialty ingredients that improve and enhance the health and well being of life
More informationartnet AG Quarterly Interim Statement for the First Quarter of 2017 artnet AG Quarterly Interim Statement for the First Quarter of 2017
Quarterly Interim Statement for the First Quarter of 2017 Quarterly Interim Statement for the First Quarter of 2017 Table of Contents General Information and Business Activities Economic Development of
More informationFor personal use only
ASX RELEASE (23 rd March 2018) AGM PowerPoint Presentaion In accordance with the requirements of Listing Rule 3.1 we submit the attached material being distributed at the Company s Annual General Meeting
More informationFriends raises funds, offers expertise, collects donations, and provides volunteer support to help:
ANNUAL REPORT 2015 1603 22 nd Street Anacortes, WA 98221 Phone: 360-293-0673 Ext. 106 FAX: 360-299-2953 Website: fidalgopool.com Friends of Fidalgo Pool and Fitness Center is a 501(c)(3) nonprofit charitable
More informationInvestor Presentation. Q October 26, 2017
Investor Presentation Q1 2018 October 26, 2017 Safe Harbor Statement Statements contained in this presentation that are not historical facts are forwardlooking statements as contemplated by the Private
More informationVontobel Viewpoints FDA New Direction on Tobacco Our Take
Quality Growth Boutique TM Vontobel Viewpoints On July 28, 2017, the new Commissioner of the U.S. Food and Drug Administration (FDA), Scott Gottlieb, surprised the markets by launching a consultation paper
More informationValue creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO
Value creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO Forward-looking statements The forward-looking statements contained in this presentation,
More informationFully Employed MBA (MGMT FE)
Fully Employed MBA (MGMT FE) 1 Fully Employed MBA (MGMT FE) Courses MGMT FE 200. Responding to Dynamic Times: Thinking Strategically in Organizations. 6 Units. Focuses on the strategic and organizational
More informationDIABETES CARE DEVICES MARKET IN BRAZIL, RUSSIA, INDIA & CHINA (BRIC)
DIABETES CARE DEVICES MARKET IN BRAZIL, RUSSIA, INDIA & CHINA (BRIC) R e p o r t D e s c r i p t i o n T a b l e o f C o n t e n t s L i s t o f T a b l e s S a m p l e T a b l e s R e l a t e d R e p
More informationPhotoCure ASA Presentation First quarter 2005 May 3, 2005
PhotoCure ASA Presentation First quarter 2005 May 3, 2005 Obtaining milestones and building value Hexvix Approval in 27 EU/EEA countries, working on national approvals Ongoing phase III study for extended
More informationMETVIX PDT ON THE MARKET IN GERMANY AND UK
METVIX PDT ON THE MARKET IN GERMANY AND UK PhotoCure ASA First Quarter Report 2003 Highlights: The launches of Metvix PDT by Galderma in February in Germany and in May in the UK, have triggered milestone
More informationDirector of Donor Partnerships
TULSA Community Foundation Tulsa Community Foundation (TCF) was founded in late 1998 and exists to make charitable giving more meaningful and efficient. Hundreds of individuals and corporations make all
More informationNovo Nordisk increased operating profit by 15% in the first six months of 2013 Sales growth of 11% driven by Victoza, NovoRapid and Levemir
report for the period 1 January 2013 to 30 June 2013 8 August 2013 Novo Nordisk increased operating profit by 15% in the first six months of 2013 Sales growth of 11% driven by Victoza, NovoRapid and Levemir
More informationJefferies Healthcare Conference
Jefferies Healthcare Conference Jean-Marc BOTHY - CSO June 8, 2017 2017 IBA SA Disclaimer This presentation may contain forward-looking statements concerning industry outlook, including growth drivers;
More informationXXII: CTP Summarizes Scientific Case for Limiting Nicotine in Cigarettes. Company Update October 15, 2018 Industrial & Consumer Technology
Company Update Industrial & Consumer Technology (XXII - $2.81 - Buy) COMPANY NOTE JAMES McILREE, CFA, Senior Research Analyst, +1-646-465-9034 jmcilree@chardan.com Sales and trading 7 a.m. to 7 p.m. ET,
More informationEmisphere Technologies, Inc. Announces 2008 Second Quarter Financial Results
August 11, 2008 Emisphere Technologies, Inc. Announces 2008 Second Quarter Financial Results Conference Call/Webcast to be Held Monday, August 11 at 10:00 AM EDT CEDAR KNOLLS, N.J., Aug 11, 2008 /PRNewswire-FirstCall
More informationIntercell and Novartis form world leading strategic partnership to drive vaccines innovation
Intercell and Novartis form world leading strategic partnership to drive vaccines innovation Alliance creates opportunity for two strong innovators to combine development efforts in attractive areas Intercell
More informationAmylin Pharmaceuticals: Creating Value as a Leader in the Treatment of Diabetes
Amylin Pharmaceuticals: Creating Value as a Leader in the Treatment of Diabetes Daniel M. Bradbury President & Chief Executive Officer JPMorgan Healthcare Conference January 12, 2009 Safe Harbor Statement
More informationMerrill Lynch's Global Pharmaceutical, Biotechnology, and Medical Device Conference. February 7, 2007
Merrill Lynch's Global Pharmaceutical, Biotechnology, and Medical Device Conference February 7, 2007 Information related to forward-looking statements This presentation includes forward-looking statements
More informationINVESTOR PRESENTATION
INVESTOR PRESENTATION May 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities regulation.
More information